|
Type I
|
Type II
|
Type III
|
Other
|
Type I
|
Type II
|
Type III
|
Other
|
Type I
|
Type II
|
Type III
|
Other
|
Incidence (%) |
40–66% (Hammack et al., 2007; Rodríguez-Sierra et al., 2013; Daniel et al., 2017) |
11–30% (Hammack et al., 2007; Rodríguez-Sierra et al., 2013; Daniel et al., 2017) |
16–30% (Hammack et al., 2007; Rodríguez-Sierra et al., 2013; Daniel et al., 2017) |
4–8% (Rodríguez-Sierra et al., 2013) |
13% (Daniel et al., 2017) |
22% (Daniel et al., 2017) |
54% (Daniel et al., 2017) |
11% (Daniel et al., 2017) |
3% (Daniel et al., 2017) |
16% (Daniel et al., 2017) |
56% (Daniel et al., 2017) |
25% (Daniel et al., 2017) |
Spiking/firing pattern |
RF,DF (Hammack et al., 2007; Rodríguez-Sierra et al., 2013; Daniel et al., 2017) |
LTB, RBF (Hammack et al., 2007; Rodríguez-Sierra et al., 2013; Daniel et al., 2017) |
RF, DF, fIR (Hammack et al., 2007; Rodríguez-Sierra et al., 2013; Daniel et al., 2017) |
LF (Rodríguez-Sierra et al., 2013) SA (Rodríguez-Sierra et al., 2013) |
RF,DF (Daniel et al., 2017; Walter et al., 2018; Miura et al., 2023) |
noRBF (Daniel et al., 2017) RBF (Walter et al., 2018; Miura et al., 2023) |
RF, DF, fIR (Daniel et al., 2017; Walter et al., 2018; Miura et al., 2023) |
fAHP (Daniel et al., 2017) |
RF,DF (Daniel et al., 2017) |
LTB, RBF (Daniel et al., 2017) |
DF, fIR (Daniel et al., 2017) |
fAHP (Daniel et al., 2017) SF (Daniel et al., 2017) |
Neuro- transmitter |
GABA (McDonald, 1983; Sun and Cassell, 1993; Hammack et al., 2007; Nguyen et al., 2016; Daniel et al., 2017) |
GABA (McDonald, 1983; Sun and Cassell, 1993; Hammack et al., 2007; Nguyen et al., 2016; Daniel et al., 2017) |
GABA (McDonald, 1983; Sun and Cassell, 1993; Hammack et al., 2007; Nguyen et al., 2016; Daniel et al., 2017) |
GABA and GLUT? (McDonald, 1983; Sun and Cassell, 1993; Hammack et al., 2007; Nguyen et al., 2016; Daniel et al., 2017) |
GABA (Daniel et al., 2017) |
GABA (Daniel et al., 2017) |
GABA (Daniel et al., 2017) |
GABA and GLUT? (Daniel et al., 2017) |
GABA (Daniel et al., 2017) |
GABA (Daniel et al., 2017) |
GABA (Daniel et al., 2017) |
GABA and GLUT? (Daniel et al., 2017) |
Ion channel expression |
Ih: HCN2 and HCN3 (Hammack et al., 2007; Hazra et al., 2011; Rodríguez-Sierra et al., 2013; Daniel et al., 2017) IA (Hammack et al., 2007; Hazra et al., 2011; Rodríguez-Sierra et al., 2013; Daniel et al., 2017) |
Ih,: HCN1-HCN4 (Hammack et al., 2007; Hazra et al., 2011; Rodríguez-Sierra et al., 2013; Daniel et al., 2017) IT: CaV3.1-3.3 (Hammack et al., 2007; Hazra et al., 2011; Rodríguez-Sierra et al., 2013; Daniel et al., 2017) |
IK(IR): Kir2.1-Kir2.4 (Hammack et al., 2007; Hazra et al., 2011; Rodríguez-Sierra et al., 2013; Daniel et al., 2017) IA (Hammack et al., 2007; Hazra et al., 2011; Rodríguez-Sierra et al., 2013; Daniel et al., 2017) |
ID (Rodríguez-Sierra et al., 2013) |
Ih (Daniel et al., 2017) IA (Hammack et al., 2007; Hazra et al., 2011; Rodríguez-Sierra et al., 2013; Daniel et al., 2017) |
Ih (Daniel et al., 2017) IT (Daniel et al., 2017) |
IK(IR) (Daniel et al., 2017) IA (Daniel et al., 2017) |
? |
Ih (Daniel et al., 2017) |
Ih (Daniel et al., 2017) IT (Daniel et al., 2017) |
IK(IR) (Daniel et al., 2017) |
? |
Neuropeptide markers |
|
Enk, PKCδ (Daniel and Rainnie, 2016) NPY, SOM (McDonald and Zaric, 2015) |
CRF (Dabrowska et al., 2013) |
? |
NPY (Walter et al., 2018) |
Enk, PKCδ (Daniel and Rainnie, 2016) NPY (Walter et al., 2018) |
CRF (Martin et al., 2010) NPY (Walter et al., 2018) |
? |
? |
? |
? |
? |
Morphology |
Medium-spiny-like, round, polygonal, fusiform (McDonald, 1983; Larriva-Sahd, 2006) |
Medium-spiny-like (Daniel et al., 2017) |
Medium-spiny-like (Fudge and Haber, 2001) Long dendrites, large arborization (Daniel et al., 2017) |